Request a Quote |

Cyprotex Highlights - June 2021


We are delighted to announce Dr Stephen Madden has joined us as SVP, Scientific and Business Operations.

Steve has over 20 years extensive experience in the CRO business, building and leading teams in in vitro sciences and the ADME space. 

Join us in welcoming Steve to Cyprotex!

Request a meeting with Steve

June 22-23, Cyprotex presented new research at the virtual HT-ADME conference.

Mark Wenlock PhD (Physical Chemistry Team Leader) presented on:

  • The Advances and Application of High Throughput Physical Chemistry Assays.

Download the presentation

Download our posters:

  • Determining Chromatographic Hydrophobicity Index (CHI) using Liquid Chromatography
  • Use of Stable Labelled GSH as an Additional Diagnostic Tool

Download the CHI poster

Download the GSH poster

Talk to us about phys chem

The Science Pool hosts all of the latest scientific research, news and insights from Evotec, Cyprotex, and Just – Evotec Biologics.

Join our online community and receive personalised updates direct to your inbox, keeping you informed on all our latest research and events.

Dive in!

Join our community

Read the latest news from parent company, Evotec:

  • Evotec launches "PRROTECT", a pre-competitive initiative to better prepare for future pandemics
  • Evotec and CEBINA launch Danube Labs to develop cutting edge biotechnology projects from Central and Eastern Europe
  • Autobahn Labs and Cold Spring Harbor Laboratory partner up to advance novel science to the clinic
  • Evotec and Bristol Myers Squibb launch "beLAB1407" and "beLAB2122" to translate innovation from UK and German leading academic institutions
  • Evotec and the GCKD study collaborate to build unique molecular patient database
  • Evotec and Bristol Myers Squibb expand partnership in targeted protein degradation
  • Evotec invests into Oxford cell therapy spinout "OxVax"
  • Evotec escalates access to biologic therapeutics with initiation of manufacturing facility in Toulouse
  • Evotec enters into partnership with Kazia Therapeutics for clinical development of EVT801
  • Evotec announces start of human clinical trials of novel immuno-oncology drug with Exscientia

Read the press releases

Contact us

News categories


Contact us to discuss your ADME Tox issues or request a quote

North America (East Coast): +1-888-297-7683
Europe: +44 (0)1625 5051000


or fill out the form below:

Please give details of the assays you are interested in. Where appropriate please specify one or more species (human, rat, mouse etc.), isoforms (CYP1A1,CYP1B1, etc) or other relevant details.

By clicking on ‘Send’ I agree that my data is being transferred and used by Cyprotex and the affiliated Evotec Group. The Evotec Group currently consists of the following companies. For further details please see our privacy policy.

If you would like to be kept informed of our latest services, new research, events and other news please tick the box below: